Literature DB >> 10843744

Circulating transforming growth factor beta(1) as an indicator of hepatic function impairment in liver cirrhosis.

R Flisiak1, B Pytel-Krolczuk, D Prokopowicz.   

Abstract

In the liver, transforming growth factor (TGF) -beta(1)is primarily responsible for activation of fat-storing cells, which are the main source of extracellular matrix proteins. Their deposition play a key role in the development of liver cirrhosis. The aim of this study was to evaluate plasma TGF-beta(1)in patients with different stages of liver cirrhosis and its possible use as an indicator of liver function impairment. TGF-beta(1)was measured in the plasma of 40 patients with liver cirrhosis. To estimate possible effect of liver insufficiency on plasma TGF-beta(1), patients were divided into three groups: A, B and C, univocal with Child-Pugh classes. Normal values were collected from 13 healthy volunteers. Liver cirrhosis resulted in a significant increase of plasma concentration of TGF-beta(1)(39.3+/-3.8 ng/ml), which doubled normal values (18.3+/-1.6 ng/ml). The highest concentrations were observed in alcoholic patients (44.4+/-4.7 ng/ml). TGF-beta(1)level increased depending on the degree of liver insufficiency, demonstrated by a significant positive correlation with Child-Pugh score (r=0.591). Values in group A were similar to normal, but were significantly elevated in groups B and C. These findings suggest possible use of plasma TGF-beta(1)measurement as an indicator of liver function impairment and possible marker of hepatic fibrosis progression in cirrhotic patients. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843744     DOI: 10.1006/cyto.1999.0660

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  25 in total

1.  Exercise-induced changes in circulating levels of transforming growth factor-beta-1 in humans: methodological considerations.

Authors:  Katja Heinemeier; Henning Langberg; Michael Kjaer
Journal:  Eur J Appl Physiol       Date:  2003-07-09       Impact factor: 3.078

Review 2.  Immunomodulatory effects of transforming growth factor-β in the liver.

Authors:  Hans-Theo Schon; Ralf Weiskirchen
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

3.  Relationship between transforming growth factor beta1 and anti-fibrotic effect of interleukin-10.

Authors:  Mei-Na Shi; Yue-Hong Huang; Wei-Da Zheng; Li-Juan Zhang; Zhi-Xin Chen; Xiao-Zhong Wang
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

4.  Effect of interferon alpha2b plus ribavirin treatment on selected growth factors in respect to inflammation and fibrosis in chronic hepatitis C.

Authors:  Panasiuk Anatol; Flisiak Robert; Prokopowicz Danuta
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

5.  Co-administration of cyclosporine an alleviates thioacetamide-induced liver injury.

Authors:  Sabrina Fan; Ching-Feng Weng
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

6.  Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader
Journal:  World J Exp Med       Date:  2012-04-20

Review 7.  Role of cannabinoids in chronic liver diseases.

Authors:  Anna Parfieniuk; Robert Flisiak
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

8.  Plasma concentration of transforming growth factor-beta1 and hepatic fibrosis in dogs.

Authors:  Stephan Neumann; Franz-Josef Kaup; Baerbel Beardi
Journal:  Can J Vet Res       Date:  2008-10       Impact factor: 1.310

9.  An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells.

Authors:  Nobuya Kurikawa; Miwa Suga; Shoko Kuroda; Keisuke Yamada; Hirokazu Ishikawa
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

10.  Circulating vascular endothelial growth factor and nitric oxide in patients with liver cirrhosis: A possible association with liver function impairment.

Authors:  Mohamed Ahmed Abdelmoaty; Ahmed Mohamed Bogdady; Mervat Mohamed Attia; Nayel Abdelhamed Zaky
Journal:  Indian J Clin Biochem       Date:  2009-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.